During the past decade, Callahan Eye Foundation Hospital conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Callahan Eye Foundation Hospital" are "Autonomic Dysfunction" (1 trials), "Cardiovascular Autonomic Neuropathy" (1 trials), "Diabetic Autonomic Neuropathy" (1 trials) and "Pterygium" (1 trials). Many other conditions were trialed in "Callahan Eye Foundation Hospital" in a lesser frequency.

Most popular intervention types in "Callahan Eye Foundation Hospital" are "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "ANSAR ANX 3.0 Software" (1 trials) and "local injection of bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Callahan Eye Foundation Hospital" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Callahan Eye Foundation Hospital". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Callahan Eye Foundation Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Callahan Eye Foundation Hospital, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".